Decriminalize Drugs & The Draft entered the industry of Specialty Outpatient Clinics, Nec in 0 and has grown to employ 1 to 4 people, generating an annual revenue of $100.000 to $499.999. The NAICS classifies this business under the code , which describes it as a Specialty Outpatient Clinics, Nec. For further clarification, the SIC classifies this business under the code and described it as a Specialty Outpatient Clinics, Nec. The business provides service to the B2C market.
To acquire more information, please contact Christopher Blake by calling (815) 741-8184 during business hours. You can also write to the business’ Single Location at 1855 Mappold Way, Joliet, Illinois IL 60435. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
| Company: | Decriminalize Drugs & The Draft |
| Representative: | Christopher Blake |
| Place of Business: | 1855 Mappold Way, Joliet, IL 60435 |
| Contact Number: | (815) 741-8184 |
| Type of Service: | Specialty Outpatient Clinics, Nec |
| Locality: | Single Location |
| Market Type: | B2C (Business to Consumer) |
| Income/Year: | $100.000 to $499.999 |
| Laborers: | 1 to 4 |
| Share This Company: |
Decriminalize Drugs & The Draft is a company operating from Will, Illinois providing professional Specialty Outpatient Clinics, Nec and relevant B2C variables. It was founded in 0 and registered with the SIC code as Specialty Outpatient Clinics, Nec, and with the NAICS code as Specialty Outpatient Clinics, Nec.
With a current employee count of 1 to 4, Decriminalize Drugs & The Draft has gone to report making $100.000 to $499.999 per annum on its journey towards growth. This company invites you to contact its representative Christopher Blake at (815) 741-8184 for related queries, or to locate its Single Location using the coordinates 41.54704,-88.12185.
The Single Location can also be found at the street address 1855 Mappold Way in Joliet, Illinois 60435 and can be engaged online through the company website at , the company Twitter , and Facebook page .